Investment Thesis
Spyre Therapeutics is a pre-revenue pharmaceutical company with zero revenue generation and quarterly cash burn of $57.4M against only $97.2M in cash reserves, providing approximately 1.7 quarters of runway. While the balance sheet shows minimal debt and strong equity position ($670.8M), the company faces imminent financing risk as operational losses (-$69.0M net loss latest period) are consuming capital with no offsetting revenue generation.
Strengths
- Minimal debt with 0.00x Debt/Equity ratio and strong stockholders equity of $670.8M
- Excellent liquidity position with 8.97x current ratio providing near-term operational flexibility
- Substantial asset base of $764.0M providing financial cushion for development activities
- Insider activity with 9 Form 4 filings suggesting some level of insider confidence
Risks
- Zero revenue generation typical of pre-clinical/early-stage biotech with no clear path to commercialization
- Severe quarterly cash burn of $57.4M with only ~1.7 quarters of runway remaining before liquidity crisis
- Large operating and net losses (-$45.6M and -$69.0M respectively) with negative ROE (-10.3%) and ROA (-9.0%)
- High execution risk dependent on successful clinical trial outcomes and FDA approval with no guaranteed success
- Imminent need for capital raise or major revenue milestone within 6 months to avoid financial distress
Key Metrics to Watch
- Cash balance and burn rate trends quarterly to monitor runway sufficiency
- Clinical trial progress and FDA milestone achievements for pipeline candidates
- Capital raising activities and any strategic partnerships or licensing deals
- Path to revenue generation timeline and commercial milestone achievements
Financial Metrics
Revenue
0.0
Net Income
-69.0M
EPS (Diluted)
$-0.74
Free Cash Flow
-57.4M
Total Assets
764.0M
Cash
97.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-10.3%
ROA
-9.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.97x
Quick Ratio
8.97x
Debt/Equity
0.00x
Debt/Assets
12.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:24:49.431261 |
Data as of: 2026-03-31 |
Powered by Claude AI